3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
7
Active not recruiting
2
Unknown
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Colorectal Neoplasms
53
Breast Neoplasms
53
Neoplasms
40
Advanced Solid Tumors
33
Prostatic Neoplasms
31
Multiple Myeloma
31
Neoplasm Metastasis
29
Recurrence
28
Ovarian Neoplasms
28
Lung Neoplasms
28
Carcinoma, Hepatocellular
28
Pancreatic Neoplasms
26
Advanced Solid Tumor
21
Small Cell Lung Carcinoma
20
Leukemia, Myeloid, Acute
20
Melanoma
18
Endometrial Neoplasms
18
Triple Negative Breast Neoplasms
17
Lymphoma, Follicular
15
Squamous Cell Carcinoma of Head and Neck
14
Stomach Neoplasms
13
Lymphoma, B-Cell
13
Glioma
13
Uterine Cervical Neoplasms
12
Head and Neck Neoplasms
12
Glioblastoma
12
Lymphoma
11
Solid Tumor
10
Myasthenia Gravis
10
Interventions
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
INDUSTRY
×
Smoldering Multiple Myeloma
×
Clear all
NCT07393282
2026-03-16
LINKER-SMM2
Regeneron Pharmaceuticals
Phase 3
Not yet recruiting
270 enrolled